Drugmaker Shire was among the fallers on Wednesday as the FTSE 100’s best quarter on record ended with a whimper.
The company slipped 0.7 per cent to £10.84 after an analyst highlighted risks to patents protecting its flagship Vyvanse treatment.
Shire hurt as Footsie tumbles
By Bryce Elder and Neil Hume
Published: September 30 2009 08:57 | Last updated: September 30 2009 21:15
You have viewed your allowance of free articles. If you wish to view more, click the button below.
